Compare CPRX & IHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPRX | IHS |
|---|---|---|
| Founded | 2002 | 2001 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 2006 | 2021 |
| Metric | CPRX | IHS |
|---|---|---|
| Price | $24.49 | $8.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $33.25 | $9.32 |
| AVG Volume (30 Days) | ★ 1.2M | 1.2M |
| Earning Date | 02-25-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.94 | N/A |
| EPS | ★ 1.71 | 1.37 |
| Revenue | $578,196,000.00 | ★ $1,765,825,000.00 |
| Revenue This Year | $19.98 | $3.61 |
| Revenue Next Year | $6.96 | $2.82 |
| P/E Ratio | $14.31 | ★ $6.01 |
| Revenue Growth | ★ 25.56 | N/A |
| 52 Week Low | $19.05 | $3.40 |
| 52 Week High | $26.58 | $8.95 |
| Indicator | CPRX | IHS |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 53.82 |
| Support Level | $23.86 | $7.78 |
| Resistance Level | $25.40 | $8.95 |
| Average True Range (ATR) | 0.80 | 0.32 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 59.84 | 43.29 |
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.